SEC Form 4 · accession 0001193125-26-266230
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Muna Bhanji
Director
Period of report
Jun 9, 2026
Accepted (ET)
Jun 10, 2026 · 6:57 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 9, 2026 | A | 9,200 | $0.00 | A | 36,403 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $12.89 | Jun 9, 2026 | A | 13,300 | A | — | Jun 8, 2036 | Common Stock | 13,300 | 13,300 | D |
Explanation of responses
- F1Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.
- F2This option was granted on June 9, 2026 with respect to 13,300 shares of Common Stock and vests in full on the earlier to occur of (a) the first anniversary of the grant date or (b) the date of the next annual meeting of stockholders following the date of grant.